Found: 57
Select item for more details and to access through your institution.
FDA approves Galafold, a triumph for Amicus.
- Published in:
- Nature Biotechnology, 2018, v. 36, n. 10, p. 913, doi. 10.1038/nbt1018-913
- By:
- Publication type:
- Article
Biotech startups woo increasing numbers of crowdfunders.
- Published in:
- Nature Biotechnology, 2017, v. 35, n. 4, p. 299, doi. 10.1038/nbt0417-299
- By:
- Publication type:
- Article
Better than breakthrough scheme snags.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 5, p. 403, doi. 10.1038/nbt0514-403b
- By:
- Publication type:
- Article
Shire shifts towards rare diseases.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 2, p. 114, doi. 10.1038/nbt0214-114
- By:
- Publication type:
- Article
10,000 rare-disease genomes sequenced.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 1, p. 7, doi. 10.1038/nbt0114-7
- By:
- Publication type:
- Article
J&J in trio of European deals.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 12, p. 1065, doi. 10.1038/nbt1213-1065b
- By:
- Publication type:
- Article
Argos attracts unorthodox backers.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 11, p. 950, doi. 10.1038/nbt1113-950a
- By:
- Publication type:
- Article
From the bottom of a DNA cocktail glass.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 10, p. 868, doi. 10.1038/nbt1013-868
- By:
- Publication type:
- Article
Forma skips tech transfer brokers.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 9, p. 777, doi. 10.1038/nbt0913-777b
- By:
- Publication type:
- Article
Biotechs to tap into Horizon 2020's $93 billion.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 9, p. 779, doi. 10.1038/nbt0913-779
- By:
- Publication type:
- Article
UCLA and GSK reconcile.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 8, p. 664, doi. 10.1038/nbt0813-664
- By:
- Publication type:
- Article
Court injunction threatens clinical data transparency push.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 7, p. 581, doi. 10.1038/nbt0713-581
- By:
- Publication type:
- Article
AstraZeneca juggernaut heads for Cambridge.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 6, p. 476, doi. 10.1038/nbt0613-476
- By:
- Publication type:
- Article
No-fee university licenses spur biotech partnerships.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 5, p. 376, doi. 10.1038/nbt0513-376
- By:
- Publication type:
- Article
Mouse platforms jostle for slice of humanized antibody market.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 4, p. 267, doi. 10.1038/nbt0413-267
- By:
- Publication type:
- Article
Biotech bonanza hits UK.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 3, p. 183, doi. 10.1038/nbt0313-183
- By:
- Publication type:
- Article
Wyss Institute to rise in Merck Serono shell.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 3, p. 188, doi. 10.1038/nbt0313-188b
- By:
- Publication type:
- Article
Startups, inventors cheer European unified patent.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 2, p. 92, doi. 10.1038/nbt0213-92c
- By:
- Publication type:
- Article
Brüstle patent holds up in Germany.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 2, p. 94, doi. 10.1038/nbt0213-94b
- By:
- Publication type:
- Article
Banking iPS cells.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 1, p. 11, doi. 10.1038/nbt0113-11
- By:
- Publication type:
- Article
First gene therapy approved.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 12, p. 1153, doi. 10.1038/nbt1212-1153
- By:
- Publication type:
- Article
Big players jostle for pole position in muscular dystrophy.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 10, p. 904, doi. 10.1038/nbt1012-904b
- By:
- Publication type:
- Article
First gene therapy nears landmark European market authorization.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 9, p. 807, doi. 10.1038/nbt0912-807
- By:
- Publication type:
- Article
Swiss hope for phoenix from Merck Serono's ashes.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 7, p. 569, doi. 10.1038/nbt0712-569
- By:
- Publication type:
- Article
Agency defies advice and rejects gene therapy for third time.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 6, p. 474, doi. 10.1038/nbt0612-474b
- By:
- Publication type:
- Article
Affymax poised to challenge Amgen.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 5, p. 377, doi. 10.1038/nbt0512-377
- By:
- Publication type:
- Article
Biotech innovators jump on biosimilars bandwagon.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 4, p. 297, doi. 10.1038/nbt0412-297a
- By:
- Publication type:
- Article
UK government unveils innovation booster.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 2, p. 125, doi. 10.1038/nbt0212-125
- By:
- Publication type:
- Article
Incyte comes of age with JAK inhibitor approval.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 1, p. 3, doi. 10.1038/nbt0112-3
- By:
- Publication type:
- Article
Corrigendum: New models emerge for commercializing university assets.
- Published in:
- 2012
- By:
- Publication type:
- Correction notice
European court bans embryonic stem cell patents.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 12, p. 1057, doi. 10.1038/nbt1211-1057
- By:
- Publication type:
- Article
Chinese inventors catch up.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 10, p. 854, doi. 10.1038/nbt1011-854b
- By:
- Publication type:
- Article
New models emerge for commercializing university assets.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 9, p. 774, doi. 10.1038/nbt0911-774
- By:
- Publication type:
- Article
TNF-α blockers and tumors.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 8, p. 672, doi. 10.1038/nbt0811-672a
- By:
- Publication type:
- Article
Blue skies ready for investors.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 6, p. 470, doi. 10.1038/nbt0611-470b
- By:
- Publication type:
- Article
p38 kinase inhibitor approved for idiopathic pulmonary fibrosis.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 4, p. 301, doi. 10.1038/nbt0411-301
- By:
- Publication type:
- Article
Boehringer splashes out on bispecific antibody platforms.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 1, p. 5, doi. 10.1038/nbt0111-5
- By:
- Publication type:
- Article
Shire's replacement enzymes validate gene activation.
- Published in:
- Nature Biotechnology, 2010, v. 28, n. 11, p. 1139, doi. 10.1038/nbt1110-1139a
- By:
- Publication type:
- Article
Sanofi-aventis snaps up microRNA maker.
- Published in:
- Nature Biotechnology, 2010, v. 28, n. 9, p. 880, doi. 10.1038/nbt0910-880
- By:
- Publication type:
- Article
Erratum: Sanofi Aventis grooms its ranks for biotech partnering.
- Published in:
- 2009
- By:
- Publication type:
- Correction notice
Sanofi Aventis grooms its ranks for biotech partnering.
- Published in:
- Nature Biotechnology, 2009, v. 27, n. 7, p. 581, doi. 10.1038/nbt0709-581
- By:
- Publication type:
- Article
Report blames NICE for hastening decline of UK biotech.
- Published in:
- Nature Biotechnology, 2009, v. 27, n. 3, p. 215, doi. 10.1038/nbt0309-215
- By:
- Publication type:
- Article
Erratum: Where to float?
- Published in:
- 2008
- By:
- Publication type:
- Correction notice
Roche consolidates grip on anti-angiogenesis market.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 10, p. 1055, doi. 10.1038/nbt1008-1055
- By:
- Publication type:
- Article
London forges £2 billion research cluster.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 10, p. 1056, doi. 10.1038/nbt1008-1056
- By:
- Publication type:
- Article
GSK slashes internal R&D.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 8, p. 840, doi. 10.1038/nbt0808-840
- By:
- Publication type:
- Article
UK passes hybrids.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 7, p. 721, doi. 10.1038/nbt0708-721b
- By:
- Publication type:
- Article
News in brief.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 2, p. 147, doi. 10.1038/nbt0208-147
- By:
- Publication type:
- Article
Priced out of the UK market.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 2, p. 151, doi. 10.1038/nbt0208-151
- By:
- Publication type:
- Article
Fractured European market undermines biosimilar launches.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 1, p. 5, doi. 10.1038/nbt0108-5
- By:
- Publication type:
- Article